Significance of serum calcitonin gene-related peptide levels in prostate cancer patients receiving hormonal therapy

Urologia Internationalis

Volumn 82, Issue 3, 2009, Pages 291-295

  Suzuki, Kazumi ^a   Kobayashi, Yutaka ^a   Morita, Tatsuo ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Calcitonin gene related peptide; Hormonal therapy; Prostate cancer; Serum level

Indexed keywords

ANTIANDROGEN; CALCITONIN GENE RELATED PEPTIDE; ESTROGEN; GONADORELIN;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BLOOD SAMPLING; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PATIENT; CASTRATION; CORRELATION ANALYSIS; HISTOLOGY; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CALCITONIN GENE-RELATED PEPTIDE; HUMANS; IMMUNORADIOMETRIC ASSAY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 65949084486     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209360     Document Type: Article

References (19)

1. di Sant'Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate: diagnostic, prognostic, and therapeutic implications. Cancer 1992;70:254-268.
2. Berruti A, Dogliotti L, Mosca A, et al: Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001;12(suppl 2):S153-S157.
3. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H: Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512-515.
4. Berruti A, Dogliotti L, Mosca A, et al: Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590-2597.
5. Kamiya N, Akakura K, Suzuki H, et al: Pre-treatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 2003;44:309- 314.
6. Lilleby W, Paus E, Skovlund E, Fossa SD: Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate 2001;46:126-133.
7. Yashi M, Muraishi O, Kobayashi Y, Tokue A, Nanjo H: Elevated serum progastrin-releasing peptide (31-98) in metastatic and andro-gen-independent prostate cancer patients. Prostate 2002;51:84-97.
8. Yashi M, Nukui A, Kurokawa S, et al: Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate 2003;56:305-312.
9. Abrahamsson PA, Dizeyi N, Alm P, di Sant'Agnese PA, Deftos LJ, Aumuller G: Calcitonin and calcitonin gene-related peptide in the human prostate gland. Prostate 2000;44:181-186.
10. Brain SD, Grant AD: Vascular actions of calcitonin gene-related peptide and adrenomedu llin. Physiol Rev 2004;84:903-934.
11. Crowe R, Chapple CR, Burnstock G: The human prostate gland: a histochemical and immunohistochemical study of neuropeptides, serotonin, dopamine beta-hydroxylase and acetylcholinesterase in autonomic nerves and ganglia. Br J Urol 1991;68:53-61.
12. Suzuki K, Kobayashi Y, Morita T: Serum calcitonin gene-related peptide levels in untreated prostate cancer patients. Int J Urol 2006;13:781-784.
13. Hammerer PG, Kattan MW, Mottet N, Prayer-Galetti T: Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer. BJU Int 2006;98:11-19.
14. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJM, van der Kwast TH, Schroder FH, van Steenbrugge GJ: Androgen deprivation of the prohormone convertase-310 human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 2000;60:741-748.
15. Pinski J, Wang Q, Quek ML, Cole A, Cooc J, Danenberg K, Danenberg PV: Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 2006;66:1136-1143.
16. Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK, Lin MF: Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen sensitive LNCaP cells. Endocr Relat Cancer 2006;13:151-161.
17. Chigurupati S, Kulkarni T, Thomas S, Shah G: Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. Cancer Res 2005;65:8519-8529.
18. Spetz AC, Pet tersson B, Varenhorst E, Theodorsson E, Thorell LH, Hammar M: Momentary increase in plasma calcitonin gene-related peptide is involved in hot flashes in men treated with castration for carcinoma of the prostate. J Urol 2001;166:1720-1723.
19. Suzuki K, Kobayashi M, Tokue A: Clinical evaluation of hot flushes developing during endocrine therapy for prostate carcinoma. Jpn J Urol 2003;94:614-620.